CNB is a tyrosine kinase inhibitor that is known to have anti-tumor activity, and the addition of PLGA and PSar to the CNB nanoparticles may enhance this activity.In the study, the CNB nanoparticles were fabricated using a double emulsion solvent evaporation method. The gene discussed is PPP3R1; the disease is neoplasm.